MCID: HRT008
MIFTS: 44

Heart Conduction Disease

Categories: Cardiovascular diseases

Aliases & Classifications for Heart Conduction Disease

MalaCards integrated aliases for Heart Conduction Disease:

Name: Heart Conduction Disease 12 15
Conduction Disorder of the Heart 30 6 74
Heart Rhythm Disease 12

Classifications:



External Ids:

Disease Ontology 12 DOID:10273
ICD9CM 36 426.6

Summaries for Heart Conduction Disease

Disease Ontology : 12 A cardiovascular system disease that involves the heart's electrical conduction system.

MalaCards based summary : Heart Conduction Disease, also known as conduction disorder of the heart, is related to progressive familial heart block, type ia and cardiac conduction defect, and has symptoms including chest pain An important gene associated with Heart Conduction Disease is AKAP10 (A-Kinase Anchoring Protein 10), and among its related pathways/superpathways are Cardiac conduction and Dopamine-DARPP32 Feedback onto cAMP Pathway. The drugs Methotrexate and leucovorin have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and endothelial, and related phenotypes are cardiovascular system and homeostasis/metabolism

Related Diseases for Heart Conduction Disease

Diseases related to Heart Conduction Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 80)
# Related Disease Score Top Affiliating Genes
1 progressive familial heart block, type ia 32.7 GJA5 SCN5A
2 cardiac conduction defect 32.4 AKAP10 KCNH2 KCNQ1 RYR2 SCN5A
3 sinoatrial node disease 32.0 GJA5 HCN4 SCN5A
4 catecholaminergic polymorphic ventricular tachycardia 31.9 CASQ2 KCNH2 RYR2 SCN5A
5 atrioventricular block 31.6 HCN4 KCNH2 KCNQ1 NPPB SCN5A
6 brugada syndrome 31.4 HCN4 KCNA5 KCND3 KCNH2 KCNQ1 SCN5A
7 atrial fibrillation 30.4 ACE CRP F2 GJA5 HCN4 KCNA5
8 short qt syndrome 10.9
9 progressive familial heart block 10.9
10 postural orthostatic tachycardia syndrome 10.9
11 atrial standstill 10.5 GJA5 SCN5A
12 familial sick sinus syndrome 10.4 HCN4 SCN5A
13 hepatoportal sclerosis 10.4 ACE F2
14 subacute cutaneous lupus erythematosus 10.4 ACE TRIM21
15 first-degree atrioventricular block 10.4 GJA5 SCN5A
16 brugada syndrome 1 10.4 KCNA5 KCNH2 SCN5A
17 long qt syndrome 13 10.4 KCNH2 KCNQ1 SCN5A
18 long qt syndrome 12 10.4 KCNH2 KCNQ1 SCN5A
19 malignant otitis externa 10.4 CRP F2
20 long qt syndrome 3 10.4 KCNH2 KCNQ1 SCN5A
21 jervell and lange-nielsen syndrome 1 10.4 KCNH2 KCNQ1 SCN5A
22 familial short qt syndrome 10.4 KCNH2 KCNQ1
23 generalized atherosclerosis 10.4 ACE CRP
24 left bundle branch hemiblock 10.4 ACE NPPB SCN5A
25 sick sinus syndrome 10.3 F2 HCN4 SCN5A
26 arteritic anterior ischemic optic neuropathy 10.3 ACE CRP F2
27 ventricular fibrillation, paroxysmal familial, 1 10.3 KCNH2 KCNQ1 RYR2 SCN5A
28 cardiac arrhythmia 10.3 KCNH2 KCNQ1 RYR2 SCN5A
29 anterolateral myocardial infarction 10.3 ACE NPPB
30 andersen cardiodysrhythmic periodic paralysis 10.3 KCNH2 KCNQ1 RYR2 SCN5A
31 long qt syndrome 2 10.3 KCNH2 KCNQ1 RYR2 SCN5A
32 ischemic heart disease 10.3 ACE CRP NPPB
33 intermittent claudication 10.3 ACE CRP F2
34 right bundle branch block 10.3 HCN4 KCND3 SCN5A
35 systolic heart failure 10.3 ACE CRP NPPB
36 abdominal tuberculosis 10.3 CRP F2
37 angina pectoris 10.3 ACE CRP NPPB
38 chronic thromboembolic pulmonary hypertension 10.3 CRP F2 NPPB
39 heart valve disease 10.3 ACE CRP NPPB
40 coronary stenosis 10.3 ACE CRP NPPB
41 peripheral vascular disease 10.3 ACE CRP F2
42 left ventricular noncompaction 10.3 HCN4 KCNQ1 RYR2 SCN5A
43 aortic valve disease 2 10.3 ACE CRP NPPB
44 arrhythmogenic right ventricular cardiomyopathy 10.3 HCN4 KCNH2 RYR2 SCN5A
45 systemic scleroderma 10.3 ACE CRP TRIM21
46 third-degree atrioventricular block 10.3 HCN4 NPPB SCN5A TRIM21
47 syncope 10.3 KCNH2 KCNQ1 NPPB SCN5A
48 ischemic neuropathy 10.3 CRP F2
49 sudden infant death syndrome 10.3 KCNH2 KCNQ1 RYR2 SCN5A
50 sleep apnea 10.3 ACE CRP NPPB

Graphical network of the top 20 diseases related to Heart Conduction Disease:



Diseases related to Heart Conduction Disease

Symptoms & Phenotypes for Heart Conduction Disease

UMLS symptoms related to Heart Conduction Disease:


chest pain

MGI Mouse Phenotypes related to Heart Conduction Disease:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.16 ACE AKAP10 CASQ2 CRP F2 GJA5
2 homeostasis/metabolism MP:0005376 9.93 ACE CASQ2 CRP F2 GJA5 KCNA5
3 mortality/aging MP:0010768 9.77 ACE AKAP10 CASQ2 F2 GJA5 HCN4
4 muscle MP:0005369 9.23 CASQ2 GJA5 HCN4 KCNA5 KCNH2 KCNQ1

Drugs & Therapeutics for Heart Conduction Disease

Drugs for Heart Conduction Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 451)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methotrexate Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 1959-05-2, 59-05-2 126941
2
leucovorin Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 58-05-9 143 6006
3
Propafenone Approved Phase 4,Not Applicable 54063-53-5 4932
4
Sotalol Approved Phase 4,Phase 3,Not Applicable 959-24-0, 3930-20-9 5253
5
Amiodarone Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 1951-25-3 2157
6
Ranolazine Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 95635-55-5, 142387-99-3 56959
7
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 137-58-6 3676
8
Verapamil Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 52-53-9 2520
9
Adenosine Approved, Investigational Phase 4,Phase 1,Not Applicable 58-61-7 60961
10
Metoprolol Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 37350-58-6, 51384-51-1 4171
11
Racepinephrine Approved Phase 4,Phase 2,Not Applicable 329-65-7 838
12
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Not Applicable 51-43-4 5816
13
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
14
Remifentanil Approved Phase 4,Not Applicable 132875-61-7 60815
15
Ajmaline Approved, Experimental Phase 4,Phase 2,Not Applicable 4360-12-7 441080
16
Procainamide Approved Phase 4,Phase 3 51-06-9 4913
17
Diltiazem Approved, Investigational Phase 4,Phase 1 42399-41-7 39186
18
Ibutilide Approved Phase 4,Phase 2 122647-31-8, 122647-32-9 60753
19
Methyltestosterone Approved Phase 4 58-18-4 6010
20
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
21
Progesterone Approved, Vet_approved Phase 4,Phase 2 57-83-0 5994
22
Testosterone Approved, Experimental, Investigational Phase 4 58-22-0, 481-30-1 10204 6013
23
Testosterone enanthate Approved Phase 4 315-37-7 9416
24
Nebivolol Approved, Investigational Phase 4 152520-56-4, 99200-09-6, 118457-14-0 71301
25
Atenolol Approved Phase 4,Phase 1,Phase 2,Not Applicable 29122-68-7 2249
26
Bisoprolol Approved Phase 4 66722-44-9 2405
27
Propranolol Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 525-66-6 4946
28
Esmolol Approved Phase 4,Phase 3,Phase 2 103598-03-4, 81147-92-4 59768
29
Mexiletine Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 31828-71-4 4178
30
Ethanol Approved Phase 4,Phase 2,Phase 3 64-17-5 702
31
Ibuprofen Approved Phase 4 15687-27-1 3672
32
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
33
Methadone Approved, Illicit Phase 4 76-99-3 4095
34
Somatostatin Approved, Investigational Phase 4,Phase 1,Phase 2 38916-34-6, 51110-01-1 53481605
35
Norepinephrine Approved Phase 4 51-41-2 439260
36 Grape Approved Phase 4
37
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
38
Dobutamine Approved Phase 4 34368-04-2 36811
39
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
40
Pasireotide Approved Phase 4,Phase 2 396091-73-9 9941444
41
Oxymetazoline Approved, Investigational Phase 4,Not Applicable,Early Phase 1 1491-59-4 4636
42
Pseudoephedrine Approved Phase 4,Not Applicable,Early Phase 1 90-82-4 7028
43
Ephedrine Approved Phase 4,Not Applicable,Early Phase 1 299-42-3 9294
44
Phenylephrine Approved Phase 4,Not Applicable,Early Phase 1 59-42-7 6041
45
Bupivacaine Approved, Investigational Phase 4 38396-39-3, 2180-92-9 2474
46
nivolumab Approved Phase 4 946414-94-4
47
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
48
Apixaban Approved Phase 4 503612-47-3 10182969
49
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 59-30-3 6037
50
Calcium Approved, Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 7440-70-2 271

Interventional clinical trials:

(show top 50) (show all 785)
# Name Status NCT ID Phase Drugs
1 Assessment of the Prognosis of Persistent Left Bundle Branch Block (LBBB)After Transcatheter Aortic Valve Implantation (TAVI ) by an Electrophysiological and Remote Monitoring Risk-adapted Algorithm Unknown status NCT02482844 Phase 4
2 Assessment of Cardiac Resynchronization Therapy in Patients With Wide QRS and Non-specific Intraventricular Conduction Delay: a Randomized Trial Unknown status NCT02454439 Phase 4
3 Safety and the Effects of Isolated Left Ventricular Pacing in Patients With Bradyarrhythmias Unknown status NCT01717469 Phase 4
4 Ivabradine in Hemodialysed Patients With Increased Heart Rate Unknown status NCT01364077 Phase 4 Ivabradine;Placebo
5 BHCG Level in Day 4,7, in Comparison to Day 10 as an Indicator for Treatment Success Unknown status NCT01860690 Phase 4 Methotrexate
6 Catheter Ablation Versus Antiarrhythmic Drugs for Outflow Tract Ventricular ARrhythmias Unknown status NCT01780311 Phase 4 antiarrhythmic drugs (Flecainide or Propafenone or Sotalol)
7 Comparative Study Between Cryoablation and Radiofrequency Ablation in the Treatment of Supraventricular Tachycardia Unknown status NCT01584154 Phase 4
8 Resynchronization in Paced Heart Failure Patients With Implantable Cardioverter Defibrillator (ICD) Indication Unknown status NCT01415024 Phase 4
9 Right Ventricular Septal Pacing for the Prevention of Left Ventricular Dysfunction in Patients With Atrio-Ventricular Block Unknown status NCT00709774 Phase 4
10 Ventricular Pacing Site Selection (V-PASS) Unknown status NCT00292383 Phase 4
11 Laparascopy Versus Laparatomy in the Management of Ruptured Ectopic Pregnancy Unknown status NCT01932957 Phase 4
12 To Evaluate the Efficacy and Safety of Wenxin Keli in Treating Atrial Premature Beats Unknown status NCT02319603 Phase 4 Low dose WenXin keli;High dose WenXin keli
13 Medical ANtiarrhythmic Treatment or Radiofrequency Ablation in Ischemic Ventricular Tachyarrhythmias Unknown status NCT02303639 Phase 4 Antiarrhythmic drug therapy
14 Study to Reduce Symptoms of Premature Beats With Ranolazine Unknown status NCT01996618 Phase 4 Ranolazine
15 Shensongyangxin Capsule in the Treatment of Sinus Bradycardia With Premature Ventricular Contractions Unknown status NCT01750775 Phase 4 Shensong Yangxin capsule;placebo Capsule
16 Shensong Yangxin Capsule in the Treatment of Heart Failure Complicated With Ventricular Premature Beat Unknown status NCT01612260 Phase 4 Shensong Yangxin capsule;placebo Capsule
17 Safety of Amiodarone and Ranolazine Together in Patients With Angina Unknown status NCT01558830 Phase 4 ranolazine;placebo
18 Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation Unknown status NCT00224341 Phase 4
19 Mode Evaluation in Sick Sinus Syndrome Trial (MODEST) Unknown status NCT00161551 Phase 4
20 Efficacy of a Pacemaker Algorithm in Promotion of the Intrinsic Heart Activity. Unknown status NCT00156741 Phase 4
21 Spontaneous Atrio Ventricular Conduction Preservation Completed NCT00655213 Phase 4
22 Syncope: Pacing or Recording in the Later Years Completed NCT01423994 Phase 4
23 Multimodal Analgesic Technique for Control of Post-laproscopy Abdominal Pain Completed NCT03241602 Phase 4 Intraperitoneal lidocaine
24 A Study of Ivabradine in African-American/ Black Subjects With Heart Failure and Left Ventricular Systolic Dysfunction. Completed NCT03456856 Phase 4 5mg Ivabradine
25 Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients. Completed NCT01966107 Phase 4 Aclidinium Bromide;Placebo
26 Speed of Recovery of Reversal of Neuromuscular Blockade in Geriatric Patients Undergoing Spine Surgery Completed NCT03112993 Phase 4 sugammadex;Neostigmine
27 Ultra-high Density Mapping With Multielectrode Catheter vs Conventional Point by Point Mapping for Ventricular Tachycardia Substrate Ablation Completed NCT02083016 Phase 4
28 Remifentanil Intravenous Patient Controlled Analgesia (IVPCA) for Ablation of Idiopathic Ventricular Tachycardia Completed NCT01901575 Phase 4 Remifentanil
29 Oral Verapamil in Acute Paroxysmal Supra Ventricular Tachycardia(PSVT) Recurrence Control Completed NCT01655316 Phase 4 Verapamil
30 Study Evaluating the Efficacy and Safety of Remifentanil in a Rapid Sequence Induction for Fragile Subjects Completed NCT01259648 Phase 4 0.5 µg/kg remifentanil;1.0 µg/kg remifentanil;NaCl
31 Radiation Exposure Reduction in Supraventricular Tachycardia Ablation Completed NCT01132274 Phase 4
32 Stereotaxis Study To Obliterate Persistent Ventricular Tachycardia Completed NCT00851279 Phase 4
33 Optimal Anti-tachycardia Therapy in Implantable Cardioverter-defibrillator (ICD) Patients Without Pacing Indications Completed NCT00729703 Phase 4
34 Biventricular Tachycardias Outcome Trial Completed NCT00729235 Phase 4
35 Ajmaline Utilization in the Diagnosis and Treatment of Cardiac Arrhythmias Completed NCT00702117 Phase 4 flecainide;ajmaline;procainamide
36 Fast VT Episodes Are Terminated by ATP One Shot Completed NCT00617578 Phase 4
37 Influence of Home Monitoring on the Clinical Status of Heart Failure Patients With an Impaired Left Ventricular Function Completed NCT00538356 Phase 4
38 Catheter Evaluation for Endocardial Ablation in Patients With Ventricular Tachycardia Completed NCT00412607 Phase 4
39 Remote Follow-up of Patients Receiving Implantable Cardioverter Defibrillator for Prophylactic Therapy Completed NCT00401466 Phase 4
40 Study to Verify Proper Detection of Supraventricular Tachyarrhythmia With Single-Lead Dual-Chamber Implantable Cardioverter-Defibrillators (ADRIA) Completed NCT00324662 Phase 4
41 The Use of Dual Chamber ICD With Special Programmed Features to Lower the Risk of Inappropriate Shock Completed NCT00787800 Phase 4
42 Optimal Pharmacological Therapy In Implantable Defibrillator Patients (OPTIC) Completed NCT00257959 Phase 4 amiodarone beta blocker sotalol
43 ASSURE Study - Arrhythmia Single Shock DFT Versus ULV: Risk Reduction Evaluation With ICD Implantations Completed NCT00231426 Phase 4
44 SMS: Substrate Modification Study in Patients Getting an Implantable Cardioverter Defibrillator (ICD) Completed NCT00170287 Phase 4
45 VAST - Ventricular Arrhythmia Suppression Trial Completed NCT00158912 Phase 4
46 INTRINSIC RV - Inhibition of Unnecessary RV Pacing With AV Search Hysteresis in ICDs Completed NCT00148967 Phase 4
47 RIGHT: Rhythm ID Going Head-to-Head Trial Completed NCT00148954 Phase 4
48 ADVANCE CRT - D: Antitachycardia Pacing (ATP) Delivery for Painless Implantable Cardioverter Defibrillator (ICD) Therapy Completed NCT00147290 Phase 4
49 ADVANCE-D: Antitachycardia Pacing (ATP) Delivery for Painless Implantable Cardioverter Defibrillator (ICD) Therapy Completed NCT00147277 Phase 4
50 LEAF - Low Energy In Atrial Fibrillation Completed NCT00157781 Phase 4

Search NIH Clinical Center for Heart Conduction Disease

Genetic Tests for Heart Conduction Disease

Genetic tests related to Heart Conduction Disease:

# Genetic test Affiliating Genes
1 Conduction Disorder of the Heart 30 AKAP10

Anatomical Context for Heart Conduction Disease

MalaCards organs/tissues related to Heart Conduction Disease:

42
Heart, Testes, Endothelial, Lung, Brain, Liver, Bone

Publications for Heart Conduction Disease

Variations for Heart Conduction Disease

Expression for Heart Conduction Disease

Search GEO for disease gene expression data for Heart Conduction Disease.

Pathways for Heart Conduction Disease

GO Terms for Heart Conduction Disease

Cellular components related to Heart Conduction Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 sarcolemma GO:0042383 9.5 KCND3 RYR2 SCN5A
2 intercalated disc GO:0014704 9.33 GJA5 KCNA5 SCN5A
3 junctional sarcoplasmic reticulum membrane GO:0014701 9.26 CASQ2 RYR2
4 Z disc GO:0030018 9.26 CASQ2 KCNA5 RYR2 SCN5A
5 voltage-gated potassium channel complex GO:0008076 8.92 KCNA5 KCND3 KCNH2 KCNQ1

Biological processes related to Heart Conduction Disease according to GeneCards Suite gene sharing:

(show all 40)
# Name GO ID Score Top Affiliating Genes
1 ion transmembrane transport GO:0034220 9.97 CASQ2 KCNQ1 RYR2 SCN5A
2 potassium ion transmembrane transport GO:0071805 9.92 HCN4 KCNA5 KCND3 KCNH2 KCNQ1
3 regulation of membrane potential GO:0042391 9.86 HCN4 KCNA5 KCNH2
4 regulation of ion transmembrane transport GO:0034765 9.85 HCN4 KCNA5 KCND3 KCNH2 KCNQ1 SCN5A
5 potassium ion transport GO:0006813 9.8 GJA5 HCN4 KCNA5 KCND3 KCNH2 KCNQ1
6 regulation of cardiac muscle contraction GO:0055117 9.77 GJA5 HCN4 RYR2
7 regulation of heart rate GO:0002027 9.76 CASQ2 HCN4 RYR2 SCN5A
8 regulation of blood vessel diameter GO:0097746 9.75 ACE GJA5 NPPB
9 membrane repolarization during ventricular cardiac muscle cell action potential GO:0098915 9.74 KCND3 KCNH2 KCNQ1
10 regulation of membrane repolarization GO:0060306 9.73 CASQ2 KCNH2 KCNQ1
11 membrane repolarization GO:0086009 9.72 KCND3 KCNH2 KCNQ1
12 membrane repolarization during cardiac muscle cell action potential GO:0086013 9.71 KCND3 KCNH2 KCNQ1
13 regulation of ventricular cardiac muscle cell membrane repolarization GO:0060307 9.71 GJA5 KCNH2 KCNQ1 SCN5A
14 atrial cardiac muscle cell action potential GO:0086014 9.69 KCNA5 KCNQ1 SCN5A
15 membrane depolarization during action potential GO:0086010 9.68 KCNH2 SCN5A
16 potassium ion homeostasis GO:0055075 9.68 KCNA5 KCNH2
17 positive regulation of potassium ion transmembrane transport GO:1901381 9.67 KCNH2 KCNQ1
18 cell communication by electrical coupling involved in cardiac conduction GO:0086064 9.67 GJA5 RYR2
19 regulation of atrial cardiac muscle cell membrane repolarization GO:0060372 9.67 KCNA5 KCNQ1 SCN5A
20 cellular response to epinephrine stimulus GO:0071872 9.66 KCNQ1 RYR2
21 detection of calcium ion GO:0005513 9.66 CASQ2 RYR2
22 regulation of blood coagulation GO:0030193 9.65 F2 VKORC1
23 membrane depolarization during cardiac muscle cell action potential GO:0086012 9.65 HCN4 SCN5A
24 regulation of atrial cardiac muscle cell membrane depolarization GO:0060371 9.65 GJA5 SCN5A
25 SA node cell action potential GO:0086015 9.65 GJA5 HCN4 SCN5A
26 cellular response to caffeine GO:0071313 9.64 CASQ2 RYR2
27 membrane repolarization during action potential GO:0086011 9.64 KCNH2 KCNQ1
28 regulation of ventricular cardiac muscle cell membrane depolarization GO:0060373 9.63 GJA5 SCN5A
29 membrane depolarization during SA node cell action potential GO:0086046 9.63 HCN4 SCN5A
30 membrane repolarization during atrial cardiac muscle cell action potential GO:0098914 9.62 KCNA5 KCNQ1
31 AV node cell to bundle of His cell communication GO:0086067 9.62 GJA5 SCN5A
32 regulation of atrial cardiac muscle cell action potential GO:0098910 9.61 GJA5 RYR2
33 regulation of AV node cell action potential GO:0098904 9.61 GJA5 RYR2
34 Purkinje myocyte to ventricular cardiac muscle cell signaling GO:0086029 9.6 CASQ2 RYR2
35 potassium ion export across plasma membrane GO:0097623 9.56 KCNA5 KCND3 KCNH2 KCNQ1
36 cardiac muscle contraction GO:0060048 9.55 CASQ2 KCNH2 KCNQ1 RYR2 SCN5A
37 ventricular cardiac muscle cell action potential GO:0086005 9.35 GJA5 KCNH2 KCNQ1 RYR2 SCN5A
38 regulation of heart rate by cardiac conduction GO:0086091 9.17 GJA5 HCN4 KCNA5 KCND3 KCNH2 KCNQ1
39 ion transport GO:0006811 10.13 HCN4 KCNA5 KCND3 KCNH2 KCNQ1 RYR2
40 transmembrane transport GO:0055085 10.03 GJA5 HCN4 KCNA5 KCND3 KCNH2 KCNQ1

Molecular functions related to Heart Conduction Disease according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 ion channel binding GO:0044325 9.76 KCND3 KCNQ1 RYR2 SCN5A
2 ion channel activity GO:0005216 9.72 HCN4 KCNA5 KCNH2 RYR2 SCN5A
3 scaffold protein binding GO:0097110 9.71 KCNA5 KCNH2 KCNQ1 SCN5A
4 delayed rectifier potassium channel activity GO:0005251 9.61 KCNA5 KCNH2 KCNQ1
5 potassium channel activity GO:0005267 9.55 HCN4 KCNA5 KCND3 KCNH2 KCNQ1
6 protein kinase A regulatory subunit binding GO:0034237 9.54 KCNQ1 RYR2
7 voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization GO:1902282 9.54 KCND3 KCNH2 KCNQ1
8 voltage-gated sodium channel activity GO:0005248 9.52 HCN4 SCN5A
9 outward rectifier potassium channel activity GO:0015271 9.51 KCNA5 KCNQ1
10 protein kinase A catalytic subunit binding GO:0034236 9.49 KCNQ1 RYR2
11 voltage-gated potassium channel activity involved in atrial cardiac muscle cell action potential repolarization GO:0086089 9.48 KCNA5 KCNQ1
12 voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarization GO:0086008 9.43 KCND3 KCNH2 KCNQ1
13 voltage-gated potassium channel activity GO:0005249 9.35 HCN4 KCNA5 KCND3 KCNH2 KCNQ1
14 voltage-gated ion channel activity GO:0005244 9.1 HCN4 KCNA5 KCND3 KCNH2 KCNQ1 SCN5A
15 identical protein binding GO:0042802 10.02 CRP HCN4 KCNH2 RYR2 TRIM21 TTR

Sources for Heart Conduction Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....